Impact of Pre-transplant and Post-transplant Remission Status of Patients on Survival in Newly Diagnosed Multiple Myeloma
The overall survival (OS) in patients with multiple myeloma (MM) has increased in the last decade due to the introduction of proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies as well as an extensive combination of autologous stem cell transplantation (ASCT) for suitable patients. The objective of this study was to examine the impact of pre-transplant and post-transplant remission status of patients on survival in newly diagnosed multiple myeloma. Two hundred and four patients with newly diagnosed MM who received an ASCT in our HSC transplant center at Hacettepe University Hospital between the years of 2001 and 2018 were evaluated in a retrospective manner. The median follow-up period was 35.9 months (range 4.2–206.4) for the entire group. The 5-year OS for pre-transplant remission status CR/VGPR patients and pre-transplant remission status PR or less patients were 79% and 68%, respectively (p = 0.09). The 5-year PFS for pre-transplant remission status CR/VGPR patients and pre-transplant remission status PR or less patients were 62% and 45%, respectively (p = 0.23). The 5-year OS for post-transplant remission status CR/VGPR group was 72% and for post-transplant remission status PR or less group was 60% (p = 0.02). The 5-year PFS in post-transplant remission status CR/VGPR patients was 48% and post-transplant remission status PR or less patients was 36% (p = 0.03). This study focuses on determination of survival outcome based on the best response obtained before and after ASCT and particularly highlights the significance of reaching CR and VGPR.
KeywordsMultiple myeloma Complete remission Very good partial response Remission status
Compliance with Ethical Standards
Conflict of interest
The authors of this paper have no conflict of interests, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included. The authors declare that they have no conflict of interest.
All of the ethical considerations had been strictly followed in accordance with the 1964 Helsinki declaration. As a standard care/action of the hospitals of the our tertiary care center, it has been recognized from the patient records that all of the studied patients had given informed consents at the time of hospitalization and before the administration of chemotherapy and other relevant diagnostic/therapeutic standard of care.
- 5.Attal M, Lauwers-Cances V, Hulin C, Facon T, Caillot D, Escoffre M et al (2015) Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). Am Soc HematolGoogle Scholar
- 9.Blanes M, Lahuerta JJ, González JD, Ribas P, Solano C, Alegre A et al (2013) Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transplant 19(1):69–74CrossRefGoogle Scholar
- 17.Morris C, Iacobelli S, Brand R, Bjorkstrand B, Drake M, Niederwieser D et al (2004) Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol 22(9):1674–1681CrossRefGoogle Scholar
- 18.Kim JS, Kim K, Cheong J-W, Min YH, Suh C, Kim H et al (2009) Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Biol Blood Marrow Transplant 15(4):463–470CrossRefGoogle Scholar